Immuneering Corporation

Welcome to the engineering conference call to discuss the company's third quarter 2025 financial results and share investigator-presented clinical case studies in pancreatic patients. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's question, we would like to ask each person to limit themselves to one question and one follow-up. As a reminder, this call is being recorded today, Wednesday, November 12th, 2025. I would now like to turn the call conference over to Lawrence Watts of New Street Investor Relations.

Thank you, operator. Joining us on the call today from engineering are Chief Executive Officer Ben Zeskin, Chief Scientific Officer Brett Hall, Chief Medical Officer Igor Moshchansky, Chief Accounting Officer and Treasurer, Mellie Morales, and E.B. Breakwood, our Chief Business Officer. During this call, management and our three investigators will refer to slides that you can find in the updated version of our corporate deck available in PDF on our I.R. website. Throughout this call, management will be making forward-looking statements, including statements related to its Phase 2A trial of the Teddy Messimp, as well as the timing of additional data from the study and the company's development plans. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties. Factors that could cause these results to be different from these statements include factors the company describes in its security filings, including its annual report on Form 10-K and our quarterly reports on Form 10-Q. Engineering undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. With that, I will turn the call over to Ben Zeskin, Chief Executive Officer of Immuneering. Ben? Thank you, Lawrence.

Good afternoon, everyone, and thank you for your interest in Immuneering. We do not always hold quarterly calls, but we try to do so when we have something interesting to share. And today, we are very fortunate to be joined by two investigators from our Phase 2A trial who will walk us through two remarkable case studies of first-line pancreatic cancer patients treated with atevimetinib in combination with fulfirinox. The investigators are Dr. Allison J. Ocean, Professor of Clinical Medicine at the Weill Medical College of Cornell University, and Dr. Gregory Bada, Associate Professor of Medicine at the Moores Cancer Center at UC San Diego. Doctors Ocean and Bada are, of course, busy individuals. We plan to start the call with their respective case studies after which we will let them get back to their patients, and then we will share a summary of the third quarter and why it was so transformational for immuneeering. In September, we shared an update on 34 first-line pancreatic cancer patients treated with a tebimetinib in combination with gemcitabine nabpaclitaxel with remarkable overall survival. We're as excited as ever about the overall survival we are seeing in that cohort, and we are very excited to share an update soon. We're currently planning to do so in the first half of 2026, possibly at a major medical meeting. Today, we wanted to talk about patients from a different arm of our study, a study of first-line pancreatic cancer patients treated with atevimetinib in combination with fulfirinox. Fulfirinox is also a standard-of-care chemotherapy in the first-line setting. Compared with gemcitabine nabpaclitaxel, it has shown slightly longer survival in pivotal studies, but with harsher side effects. So it's typically given to younger, higher fitness patients at centers that are well equipped to manage the harsher side effects. A tebumentinib in combination with gemcitabine nabpaclitaxel remains our top priority because the chemotherapy itself is so much better tolerated and the overall survival we have reported is so encouraging. That being said, Down the road, the ability to combine a tebumentinib with fulfirinox may ultimately give oncologists more options. And certainly, when we see remarkable outcomes in this cohort, it just lends further robustness to the data we have previously reported and highlights the tebumentinib's potential to drive differentiated outcomes for cancer patients. With that introduction, let me hand the call over to Dr. Ocean, who will walk you through the first case study.